Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway

Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib i...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncol Res
Main Authors: Tan, Wenliang, Zhu, Sicong, Cao, Jun, Zhang, Lei, Li, Wenda, Liu, Kairui, Zhong, Jinyi, Shang, Changzhen, Chen, Yajin
Format: Artigo
Sprog:Inglês
Udgivet: Cognizant Communication Corporation 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841021/
https://ncbi.nlm.nih.gov/pubmed/28276313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504017X14886444100783
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker